GlycoMimetics
Develop treatments for diseases as sickle cell and cancer.
Launch date
Employees
Market cap
$11.0m
Enterprise valuation
($11m) (Public information from Sep 2024)
Share price
$0.17 GLYC
Gaithersburg Maryland (HQ)
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 10.2m | 1.2m | <1m | <1m | - | 2.7m | <1m |
| % growth | - | (89 %) | (94 %) | (87 %) | - | - | (64 %) |
| EBITDA | (51.5m) | (63.4m) | (47.4m) | (39.1m) | - | - | - |
| % EBITDA margin | (507 %) | (5470 %) | (63204 %) | (391214 %) | - | - | - |
| Profit | (51.0m) | (63.4m) | (46.7m) | (36.9m) | (32.3m) | (38.3m) | (43.8m) |
| % profit margin | (502 %) | (5468 %) | (62251 %) | (368994 %) | - | (1434 %) | (4614 %) |
| EV / revenue | 17.7x | 64.2x | 2117.3x | 15200.0x | - | 4.3x | 12.0x |
| EV / EBITDA | -3.5x | -1.2x | -3.4x | -3.9x | - | - | - |
| R&D budget | 44.9m | 47.5m | 28.4m | 20.1m | - | - | - |
| R&D % of revenue | 442 % | 4094 % | 37855 % | 200717 % | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
$4.3m | Series A | ||
$5.1m | Series A | ||
$15.4m | Series B | ||
$38.0m | Series C | ||
| N/A | $39.0m | Convertible | |
| N/A | N/A | IPO | |
* | N/A | $19.0m | Post IPO Equity |
| N/A | $92.6m | Post IPO Equity | |
* | N/A | $100m | Post IPO Equity |
| Total Funding | $102m | ||
Related Content
Recent News about GlycoMimetics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.